BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,180,824 shares of BioLife Solutions Inc. common stock, representing 10.8% of the class as of December 31, 2025. The firm has sole power to vote and dispose of all reported shares, with no shared voting or dispositive power.
The filer is classified as an investment adviser and states that the shares were acquired and are held in the ordinary course of business. It also certifies that the holdings are not intended to change or influence control of BioLife Solutions and expressly denies being the beneficial owner of the securities beyond what is required for reporting.
BioLife Solutions Inc. executive vice president and chief scientific officer Aby J. Mathew reported a small insider sale of company stock. On 12/09/2025, he sold 631 shares of common stock at $25.13 per share. After this transaction, he directly owns 349,755 shares of BioLife Solutions common stock.
The filing states that this sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, which was adopted effective 03-08-2024. The purpose of the plan was to sell shares to cover tax withholding obligations arising from the vesting of restricted stock, indicating this was an automated, tax-related transaction rather than a discretionary open-market sale.
BioLife Solutions Inc.'s Chief Financial Officer reported a sale of company stock under a pre-arranged Rule 10b5-1(c) trading plan. On 12/09/2025, the officer sold 1,033 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 151,736 shares of BioLife Solutions common stock in direct ownership. The filing explains that the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions Inc. reported insider share sales by its Chief Human Resources Officer. The officer sold 233 shares of common stock on 12/09/2025 at $25.13 per share and 713 shares on 12/15/2025 at $24.46 per share. After these transactions, the officer beneficially owns 76,006 shares directly. The sales were made under a Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock.
BioLife Solutions Inc. director Amy DuRoss reported a sale of company stock. On 12/15/2025, she sold 2,000 shares of BioLife Solutions common stock at a price of $24.6 per share. After this transaction, she beneficially owned 18,687 shares, held directly.
BioLife Solutions Inc. reported an insider stock sale by its Chief Marketing Officer. On 12/09/2025, the officer sold 358 shares of common stock at a price of $25.13 per share. After this transaction, the officer beneficially owned 132,908 shares in a direct capacity.
The sale was made under a Rule 10b5-1(c) trading plan that the reporting person adopted effective 03-08-2024 to cover tax withholding obligations tied to the vesting of restricted stock. This indicates the transaction was pre-arranged for tax purposes rather than a discretionary open-market sale.
BioLife Solutions Inc. officer Karen A. Foster, Chief Quality and Operations, reported a small stock sale in a Form 4 filing. On 12/09/2025, she sold 519 shares of common stock at $25.13 per share. This transaction was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 03-08-2024 to cover tax withholding obligations from the vesting of restricted stock. After this sale, she directly holds 192,319 shares of BioLife Solutions common stock.
BioLife Solutions Inc. (BLFS) reported an insider stock sale by a board director. Director Amy DuRoss filed a Form 4 disclosing three open-market sales of BLFS common stock on 11/19/2025, 11/20/2025, and 11/21/2025. The reported transactions were sales of 477 shares at $24.50, 4,523 shares at $24.51, and 1,000 shares at $26.00, all coded as dispositions. After these trades, DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock in direct ownership.
BioLife Solutions, Inc.
BioLife Solutions (BLFS) disclosed insider stock sales by its President and CEO, who is also a Director. The filing reports three open‑market sales of Common Stock: 35,417 shares at a weighted average price of $26.15 on 11/11/2025; 33,418 shares at $25.88 on 11/12/2025; and 31,165 shares at $25.33 on 11/13/2025.
Following these transactions, the executive’s directly held shares moved from 454,581 to 421,163 and then to 389,998. Each price is a weighted average, with individual trades executed within disclosed ranges.